Our research and previous studies consistently demonstrate the crucial role of AXL in the tumor mesenchymal phenotype and immune evasion,[36, 59] indeed, the small molecule inhibitors targeting AXL are currently under clinical evaluation, however, Markus et al. The gene discussed is AXL; the disease is neoplasm.